PL Thomas, in alliance with Laila Nutraceuticals, has announced results of a study (published in the April, 2005 issue of DNA and Cell Biology) using their dietary supplement ingredient, 5-LOXIN[r]. The study identifies anti-inflammatory and collagen-sparing mechanisms associated with this patent-pending dietary supplement, 3-acetyl-11-keto-beta boswellic acid (AKBA). The study looked at the human genome and inflammatory pathways and compared 5-LOXIN to ibuprofen in an animal model. 5-LOXIN was shown to inhibit the expression of matrix metalloproteinase (MMP) enzymes that selectively destroy peptide bonds and structural proteins, such as collagen and cartilage. The expression of molecules involved in inflammation was significantly inhibited by 5-LOXIN. PL Thomas,, 973-984-0900,